National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,742 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
2,051 of 2,487 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
3,257 total, page 38 of 66
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
NCT00474812
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
NCT00458731
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00481078
Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT00492401
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
NCT00433537
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
NCT00478140
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
NCT00478426
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
NCT01445340
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
NCT00470054
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
NCT00470301
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT00470470
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
NCT00470197
Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus
NCT00474903
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
NCT00462605
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
NCT00459108
Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments
NCT01445314
Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer
NCT00923377
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00453154
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
NCT00433381
111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer
NCT01445054
Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
NCT00468910
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
NCT00459212
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
NCT00462553
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
NCT00398515
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
NCT00459862
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
NCT00454363
Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00459342
Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate
NCT00459407
Safety of Batracylin in Patients With Solid Tumors and Lymphomas
NCT00450502
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
NCT00450463
Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers
NCT01445327
Natural History Study of HIV Acquired in Infancy or Childhood
NCT00924365
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
NCT00438464
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00429793
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
NCT00450619
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT00451048
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer
NCT00450229
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
NCT00458978
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT00408005
Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer
NCT00435214
An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection
NCT01445145
Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta
NCT00443313
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
NCT00423735
Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation
NCT01445132
Evaluation of Blood Vessel Formation in Endocrine Tumors
NCT00923780
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
NCT00445588
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
NCT00397384
VEGF Trap in Treating Patients With Metastatic Breast Cancer
NCT00369655
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
NCT00379080
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
NCT00381940
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Cancer Institute (NCI): open-pipeline peers nationwide
Peers matched on 3,257 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Cancer Institute (NCI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3,257 trials (± recruiting share)
- Mayo Clinic · 2,844 trials · 19% recruiting
- M.D. Anderson Cancer Center · 2,692 trials · 20% recruiting
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Abiomed · 10% recruiting · 20 trials
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
Related
What to do with this National Cancer Institute (NCI) page
3,257 registered trials is a research-attention snapshot, not an endorsement of National Cancer Institute (NCI) or any single study.
- 326 of National Cancer Institute (NCI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Malignant Solid Neoplasm is the condition National Cancer Institute (NCI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Malignant Solid Neoplasm trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Cancer Institute (NCI) pipeline card: 3,257 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.